Drug intelligence / Profile preview

emedastine

Development stage: Unknown
Lead developer: Alcon
Modality: Small Molecules
Administration: Ophthalmic

Overview

Emedastine is a second-generation, selective histamine H1 receptor antagonist used primarily in ophthalmic (eye drop) form to treat symptoms of allergic conjunctivitis, such as redness, itching, and swelling of the eyes. It works by blocking the action of histamine released during allergic reactions in the eye. Emedastine exhibits high selectivity for H1 receptors with minimal activity at other histamine or neurotransmitter receptors and has a rapid onset of action. The drug was developed by Alcon, a company specializing in eye care products.

Brand names: Emadine
Other names: emedastine difumarate

Targets

HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on emedastine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on emedastine.

Explore the full profile